Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2020 Feb 22.

Published in final edited form as: Mol Pharm. 2019 Jun 27;16(8):3414–3429. doi: 10.1021/acs.molpharmaceut.9b00208

Table 4.

Pharmacokinetic Parameters of Plain Fasudil and Various Formulations after IT and IV Administration into PAH and Sham Rats^a

		C_max (ng/mL)		t_1/2 (h)		AUC_0-inf (ng·h/mL)
drug/formulations	route	Sham	PAH	Sham	PAH	Sham	PAH
plain fasudil	IV	14 150 ± 1050		0.2 ± 0.004		5967.1 ± 25.9
fasudil in no-CAR-liposome	IV	11 700 ± 778.9	10 365 ± 1135	0.3 ± 0.05	0.4 ± 0.1	9737.9 ± 544.3	9537.3 ± 1204
CAR pretreatment then fasudil no-CAR-liposomes	IV	13 200 ± 1186	12 200 ± 1268^****	0.5 ± 0.06	0.35 ± 0.1	11 890.8 ± 975.3^***	6118.8 ± 520^*
fasudil in CAR-liposome	IV	12 466.7 ± 1302^****	4080 ± 630^*	0.7 ± 0.3	1.1 ± 0.3	5213 ± 152.8	1274 ± 218
plain fasudil	IT	3035 ± 635		0.7 ± 0.08		5967.1 ± 25.9
fasudil in no-CAR-liposomes	IT	1433.3 ± 87	1183.3 ± 83	3.3 ± 1.3^*	4.7 ± 0.9^*	9737.9 ± 544.3	10 191.8 ± 2016
CAR pretreatment then fasudil in no-CAR-liposome	IT	1390 ± 150	1085 ± 45	3.9 ± 0.1	6.9 ± 1.8	11 890.8 ± 975.3^*	12 677.1 ± 2910^****
fasudil in CAR-liposome	IT	614 ± 102	379.7 ± 11.9	12.9 ± 4.6^***	16.1 ± 4.1^***	5832 ± 1365	4210.6 ± 985

^a

Data represent mean ± SD, n = 3;

^*

p < 0.05,

^**

p < 0.005,

^***

p < 0.001,

^****

p < 0.001.